Very good point. Taking that statistic into account would also significantly adjust upwards the probability of trial success and therefore the valuation shown in the Argonaut research note.
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-643
-
- There are more pages in this discussion • 358 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.005(1.56%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.0¢ | $1.379M | 4.338M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 195746 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 90580 | 4 |
View Market Depth
| Last trade - 14.42pm 05/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |